Resource Type

Journal Article 4

Year

2021 1

2019 1

2018 1

2012 1

Keywords

t(8 3

leukemia 2

21) 1

21) AML 1

21)(q22 1

AML 1

AML1-ETO 1

AML1–ETO 1

CD34+ 1

CD34+CD117dim/ CD34+CD117bri cell population 1

Kasumi-1 1

c-KIT 1

cytarabine 1

gene expression 1

hematopoiesis 1

homoharringtonine 1

mouse model 1

mutation 1

oridonin 1

pathway hits 1

open ︾

Search scope:

排序： Display mode:

AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches

Megan A. Hatlen, Lan Wang, Stephen D. Nimer

Frontiers of Medicine 2012, Volume 6, Issue 3,   Pages 248-262 doi: 10.1007/s11684-012-0206-6

Abstract:

The AML1-ETO fusion transcription factor is generated by the t(8;21) translocation, which is presentin approximately 4%–12% of adult and 12%–30% of pediatric acute myeloid leukemia (AML) patientsBoth human and mouse models of AML have demonstrated that AML1-ETO is insufficient for leukemogenesis-ETO to induce AML in vivo.We also discuss potential therapeutic strategies for t(8;21) positive AML that involve targeting the

Keywords： AML1-ETO     mouse model     leukemia     t(8     21)     pathway hits     mutation     hematopoiesis     Kasumi-1     CD34+    

HTML PDF Collect

Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia

Weina Zhang, Ying Lu, Tao Zhen, Xinjie Chen, Ming Zhang, Ping Liu, Xiangqin Weng, Bing Chen, Yueying Wang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 388-397 doi: 10.1007/s11684-018-0624-1

Abstract: Collaboration of c-KIT mutations with AML1–ETO (AE) has been demonstrated to induce t(8; 21) acute myeloidleukemia (AML).therapies designed to eliminate AE and c-KIT oncoproteins may facilitate effective treatment of t(8; 21) AMLfeatures activity against tumor cells harboring c-KIT mutations, whereas oridonin can induce t(8; 21) AMLTherefore, studies should explore the efficacy of combination therapy with oridonin and HHT in t(8; 21) AML

Keywords： AML1–ETO     c-KIT     homoharringtonine     oridonin     t(8     21) AML     synergistic effect    

HTML PDF Collect

Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report

Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song, Delong Liu

Frontiers of Medicine 2018, Volume 12, Issue 5,   Pages 593-599 doi: 10.1007/s11684-018-0635-y

Abstract: combination therapies have not resulted in considerable progress in the treatment of acute myeloid leukemia (AMLElderly patients with AML and poor risk factors have grave prognosis.Midostaurin has been recently approved for the treatment of FLT-3-mutated AML.Here, we present a case of a male patient with poor performance status and who developed AML followingThe patient with high risk AML achieved complete response to the combined treatment regimen of low-dose

Keywords： venetoclax     cytarabine     AML     leukemia    

HTML PDF Collect

Clinical significance of CD34+CD117dim/CD34+CD117bri myeloblast-associated gene expression in t(8;21) acute myeloid leukemia

Xueping Li, Yuting Dai, Bing Chen, Jinyan Huang, Saijuan Chen, Lu Jiang

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 608-620 doi: 10.1007/s11684-021-0836-7

Abstract: t(8;21)(q22;q22) acute myeloid leukemia (AML) is a highly heterogeneous hematological malignancy withleukemic myeloblast populations (CD34 CD117 and CD34 CD117 ) were previously identified in t(8;21) AMLwe examined the impact of CD34 CD117 /CD34 CD117 myeloblast-associated gene expression on t(8;21) AMLIn this study, 85 patients with t(8;21) AML were enrolled.CD117 myeloblast-associated gene expression may provide new clinically prognostic markers for t(8;21) AML

Keywords： t(8     21)(q22     q22) AML     CD34+CD117dim/ CD34+CD117bri cell population    

HTML PDF Collect

Title Author Date Type Operation

AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches

Megan A. Hatlen, Lan Wang, Stephen D. Nimer

Journal Article

Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia

Weina Zhang, Ying Lu, Tao Zhen, Xinjie Chen, Ming Zhang, Ping Liu, Xiangqin Weng, Bing Chen, Yueying Wang

Journal Article

Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report

Bingshan Liu, Roshni Narurkar, Madhura Hanmantgad, Wahib Zafar, Yongping Song, Delong Liu

Journal Article

Clinical significance of CD34+CD117dim/CD34+CD117bri myeloblast-associated gene expression in t(8;21) acute myeloid leukemia

Xueping Li, Yuting Dai, Bing Chen, Jinyan Huang, Saijuan Chen, Lu Jiang

Journal Article